中国继续医学教育
中國繼續醫學教育
중국계속의학교육
CHINA CONTINUING MEDICAL EDUCATION
2015年
12期
119-119
,共1页
胰腺癌%IRF-2%吉西他滨%化疗敏感性
胰腺癌%IRF-2%吉西他濱%化療敏感性
이선암%IRF-2%길서타빈%화료민감성
Pancreatic cancer%IRF-2%Gemcitabine chemosensitivity
目的:分析与探讨IRF-2在胰腺癌中的功能及其对胰腺癌细胞化疗敏感性的影响。方法采用METT检测吉西他滨对胰腺癌细胞株MIAPaCa-2与PANC-1的半数计量,对以上两种细胞对胰腺癌细胞化疗敏感程度加以了解,选择较为耐药的细胞对IRF-2对胰腺癌细胞化疗敏感性的影响进行进一步探讨。结果 MIAPaCa-2与PANC-1细胞中均存在IRF-2基因表达,PANC-1细胞中比MIAPaCa-2高,吉西他滨对MIAPaCa-2细胞半数有效剂量明显低于PANC-1,P<0.05,药物作用72 h后,干扰IRF-2表达细胞IC50值低于PANC-1对照细胞,由此表明,IRF-2基因表达下调后,提升了PANC-1细胞对胰腺癌细胞化疗敏感性。结论研究表明,IRF-2干扰技术特异性能够有效提升PANC-1胰腺癌细胞对吉西他滨的化疗敏感性。
目的:分析與探討IRF-2在胰腺癌中的功能及其對胰腺癌細胞化療敏感性的影響。方法採用METT檢測吉西他濱對胰腺癌細胞株MIAPaCa-2與PANC-1的半數計量,對以上兩種細胞對胰腺癌細胞化療敏感程度加以瞭解,選擇較為耐藥的細胞對IRF-2對胰腺癌細胞化療敏感性的影響進行進一步探討。結果 MIAPaCa-2與PANC-1細胞中均存在IRF-2基因錶達,PANC-1細胞中比MIAPaCa-2高,吉西他濱對MIAPaCa-2細胞半數有效劑量明顯低于PANC-1,P<0.05,藥物作用72 h後,榦擾IRF-2錶達細胞IC50值低于PANC-1對照細胞,由此錶明,IRF-2基因錶達下調後,提升瞭PANC-1細胞對胰腺癌細胞化療敏感性。結論研究錶明,IRF-2榦擾技術特異性能夠有效提升PANC-1胰腺癌細胞對吉西他濱的化療敏感性。
목적:분석여탐토IRF-2재이선암중적공능급기대이선암세포화료민감성적영향。방법채용METT검측길서타빈대이선암세포주MIAPaCa-2여PANC-1적반수계량,대이상량충세포대이선암세포화료민감정도가이료해,선택교위내약적세포대IRF-2대이선암세포화료민감성적영향진행진일보탐토。결과 MIAPaCa-2여PANC-1세포중균존재IRF-2기인표체,PANC-1세포중비MIAPaCa-2고,길서타빈대MIAPaCa-2세포반수유효제량명현저우PANC-1,P<0.05,약물작용72 h후,간우IRF-2표체세포IC50치저우PANC-1대조세포,유차표명,IRF-2기인표체하조후,제승료PANC-1세포대이선암세포화료민감성。결론연구표명,IRF-2간우기술특이성능구유효제승PANC-1이선암세포대길서타빈적화료민감성。
Objective The purpose of the analysis and discussion of IRF-2 in pancreatic function and its chemosensitivity of pancreatic cancer cells. MethodsTo detect METT gemcitabine in pancreatic cancer cell lines MIAPaCa-2 and PANC-1 half measurement of these two cells to understand the sensitivity of chemotherapy for pancreatic cancer cells, select the cells more resistant to IRF-2 in pancreatic cancer cells chemosensitivity be further explored. Results MIAPaCa-2 and PANC-1 cells exist in IRF-2 gene expression, PANC-1 cells than MIAPaCa-2 high, gemcitabine MIAPaCa-2 cells median effective dose was significantly lower than PANC-1, P<0.05, drugs for 72h after interference IRF-2-expressing cells IC50 values below PANC-1 control cells, which showed that downregulation of IRF-2 gene, to enhance the PANC-1 cells to pancreatic cancer cell sensitivity to chemotherapy.Conclusion The study shows that, IRF-2 specific interference technology can effectively enhance chemosensitivity PANC-1 pancreatic cancer cells to gemcitabine.